When Xaira Therapeutics debuted in 2024 with a gobsmacking $1 billion in funding, a natural expectation would have been for a flurry of further activity to follow. | When Xaira Therapeutics first ...
Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...
Novartis is paying Abogen Biosciences $575 million upfront for an mRNA-encoded T-cell engager (TCE) that showed early clinical promise in autoimmune disease. The deal, which inclu ...
Adecto Pharmaceuticals’ 12-year story has come to an end as the immunotherapy biotech blamed a “risk-averse funding environment” for shutting up shop. | Adecto Pharmaceuticals’ 12-year story has come ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results